Navigation Links
Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial
Date:8/24/2009

NATICK, Mass., Aug. 24 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing final results from the landmark MADIT-CRT trial on Tuesday, September 1, at 8:00 a.m. ET / 2:00 p.m. Barcelona time.

The call will be hosted by Ray Elliott, President and Chief Executive Officer; Fred Colen, Executive Vice President and Group President, Cardiac Rhythm Management; and Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the trial.

The final results from the MADIT-CRT trial will be presented during a Hot Line session at the European Society of Cardiology (ESC) Congress in Barcelona and published in a major peer-reviewed journal. The Company plans to issue a press release simultaneous with an ESC Hot Line press conference to be held in Barcelona on September 1.

The live webcast and archived replay of this call will be available at www.bostonscientific.com in the Investor Relations section. The webcast is also being distributed over Thomson Financial's Investor Distribution Network via two locations: www.earnings.com, which is accessible to the public, and www.streetevents.com, a password-protected event management site.

To ensure a timely connection to the live webcast it is recommended that users register at least 15 minutes before the webcast begins. A replay of the webcast will begin at approximately 11:00 a.m. ET on September 1 and will be available for one year.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

    CONTACT:  Paul Donovan
              508-650-8541
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696
              Investor Relations
              Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
2. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
3. Boston Scientific to Participate in Wachovia Conference
4. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
5. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
6. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
7. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
8. Boston Scientific Welcomes Launch of Syntax Score Website
9. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
10. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
11. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):